Please use this identifier to cite or link to this item:
|Title:||Quantification of trans-2,6-difluoro-4'-N,N-dimethylaminostilbene in rat plasma: Application to a pharmacokinetic study||Authors:||Lin, H.-S.
|Keywords:||Absolute oral bioavailability
|Issue Date:||18-Jan-2013||Citation:||Lin, H.-S., Sviripa, V.M., Watt, D.S., Liu, C., Xiang, T.-X., Anderson, B.D., Ong, P.S., Ho, P.C. (2013-01-18). Quantification of trans-2,6-difluoro-4'-N,N-dimethylaminostilbene in rat plasma: Application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 72 : 115-120. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jpba.2012.09.027||Abstract:||trans-2,6-Difluoro-4'-N,N-dimethylaminostilbene (DFS), a synthetic stilbene, displayed potent pre-clinical anti-cancer activities exceeding that observed for naturally occurring resveratrol. In this study, a simple and sensitive HPLC method was developed and validated to quantify DFS in rat plasma. The lower limit of quantification (LLOQ) was 5ng/ml. The intra- and inter-day variation in terms of relative standard deviation (RSD) was all less than 10%. The bias rate ranged from -11.5% to 6.2% while the absolute recovery ranged from 94.1±2.3 to 97.3±4.4%. The pharmacokinetic profiles of DFS were examined in Sprague-Dawley rats after intravenous administration (2 mg/kg). DFS displayed moderate clearance (Cl=61.5±17.7ml/min/kg) and a relatively prolonged terminal elimination half-life (t1/2 λz) of 351±180min. Aqueous solubility played a crucial role in the oral absorption of DFS. When DFS was given as a suspension (6mg/kg), the absolute oral bioavailability (F) was almost negligible. However, when DFS was given in a solution prepared with hydroxypropyl-β-cyclodextrin (6mg/kg), the F was 12.4±10.7%. Dose-escalation to 15mg/kg resulted in much higher systemic exposure (F=40.2±10.0%). As DFS is orally available after formulation with hydroxypropyl-β-cyclodextrin and pharmacologically active systemic concentrations could be achieved after a single oral dose, the use of DFS as a cancer chemopreventive/chemotherapeutic agent is possible. © 2012 Elsevier B.V.||Source Title:||Journal of Pharmaceutical and Biomedical Analysis||URI:||http://scholarbank.nus.edu.sg/handle/10635/106279||ISSN:||07317085||DOI:||10.1016/j.jpba.2012.09.027|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Nov 14, 2019
WEB OF SCIENCETM
checked on Nov 6, 2019
checked on Nov 9, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.